Gastric Cancer Testing Market: By Test (Immunohistochemistry (IHC), Fluorescent in situ hybridization (FISH)), By Product (Kits and Reagents), By Gastric Cancer Type (Adenocarcinoma, Lymphoma, Gastrointestinal stromal tumor (GIST), and Carcinoid Tumor), By End User (Hospitals, Diagnostic Centers, and Others), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Gastric Cancer Testing Market size is valued at USD 2.1 billion in 2022 and is expected to grow at a significant CAGR of 17.9% from 2023-2029. Cancer begins in the body when the cells in the body grow without any control. Cells present in any part of the body can develop cancer, which tend to spread to the other parts of the body. Gastric cancer is a type of cancer that starts in the stomach. The gastric cancer is also called as the stomach cancer. The progression of this cancer is slow. The advancement in the growth of the tumor leads serious complications. The treatment depends on the stage of the cancer. The early diagnosis helps in improving the survival rates. Cancer is caused by uncontrolled abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumour, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as gastric cancer or stomach cancer. Diet and stomach disorders are both risk factors for gastric cancer. Indigestion and stomach pain or discomfort are signs of gastric cancer. The global gastric cancer testing market is expected to develop due to an increase in the incidence of gastrointestinal tumours, lymphoma, and adenocarcinoma, as well as an increase in alcohol use, smoking, and the geriatric population. However, the global gastric cancer testing market is expected to be hampered by tight government regulations and high testing costs.

 

Gastric Cancer Testing Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

17.9%

Largest Market

Asia Pacific

Fastest Growing Market

North America
Gastric Cancer Testing Market Dynamics

Increase in the prevalence of gastrointestinal tumors, adenocarcinoma, lymphoma etc. and change in the lifestyles are majorly driving the growth of the gastric cancer testing market. Various factors such as increasing alcohol consumption and smoking is anticipated to drive the growth of the gastric cancer testing market. However, the stringent government regulations for the approval would hamper the growth of the market. The high cost involved in the testing would restrain the growth of the gastric cancer testing market.

Key Features of the Reports

  • The gastric cancer testing market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Gastric Cancer Testing Market Segmentation

By Test
  • Immunohistochemistry (IHC)
  • Fluorescent in situ hybridization (FISH)
By Product
  • Kits
  • Reagents
By Gastric Cancer Type
  • Adenocarcinoma
  • Lymphoma
  • Gastrointestinal stromal tumor (GIST)
  • Carcinoid tumor
By End User
  • Hospitals
  • Diagnostic centers
  • Others
By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The gastric cancer testing market size was valued at USD 2.1 billion in 2022.

The key segments covered in the restless leg’s syndrome market are technology, components, application, and end-users.

The gastric cancer testing market key players are Agilent Technologies Inc (U.S), Thermo Fisher Scientific Inc (U.S), Illumina Inc (Denmark), Becton, Dickinson and Company (U.S), GE Healthcare (U.K), QIAGEN N.V (Netherlands), Abbott Laboratories Inc (U.S), Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Philips Healthcare (U.K), R. Bard Inc (U.S)

1.Executive Summary
2.Global Gastric Cancer Testing Market Introduction 
2.1.Global Gastric Cancer Testing Market  - Taxonomy
2.2.Global Gastric Cancer Testing Market  - Definitions
2.2.1.Test
2.2.2.Product
2.2.3.Gastric Cancer Type
2.2.4.End User
2.2.5.Region
3.Global Gastric Cancer Testing Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Gastric Cancer Testing Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Gastric Cancer Testing Market  By Test, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Immunohistochemistry (IHC)
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Fluorescent in situ hybridization (FISH)
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Gastric Cancer Testing Market  By Product, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Kits
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Reagents
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.Global Gastric Cancer Testing Market  By Gastric Cancer Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Adenocarcinoma
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Lymphoma
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Gastrointestinal stromal tumor (GIST)
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Carcinoid tumor
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Gastric Cancer Testing Market  By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. Hospitals
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Diagnostic centers
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Others
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Gastric Cancer Testing Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Gastric Cancer Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Test Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Immunohistochemistry (IHC)
10.1.2.Fluorescent in situ hybridization (FISH)
10.2.  Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Kits
10.2.2.Reagents
10.3.  Gastric Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Adenocarcinoma
10.3.2.Lymphoma
10.3.3.Gastrointestinal stromal tumor (GIST)
10.3.4.Carcinoid tumor
10.4.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospitals
10.4.2.Diagnostic centers
10.4.3.Others
10.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Gastric Cancer Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Test Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Immunohistochemistry (IHC)
11.1.2.Fluorescent in situ hybridization (FISH)
11.2.  Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Kits
11.2.2.Reagents
11.3.  Gastric Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Adenocarcinoma
11.3.2.Lymphoma
11.3.3.Gastrointestinal stromal tumor (GIST)
11.3.4.Carcinoid tumor
11.4.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospitals
11.4.2.Diagnostic centers
11.4.3.Others
11.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
12.Asia Pacific (APAC) Gastric Cancer Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Test Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Immunohistochemistry (IHC)
12.1.2.Fluorescent in situ hybridization (FISH)
12.2.  Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Kits
12.2.2.Reagents
12.3.  Gastric Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Adenocarcinoma
12.3.2.Lymphoma
12.3.3.Gastrointestinal stromal tumor (GIST)
12.3.4.Carcinoid tumor
12.4.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospitals
12.4.2.Diagnostic centers
12.4.3.Others
12.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Gastric Cancer Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Test Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Immunohistochemistry (IHC)
13.1.2.Fluorescent in situ hybridization (FISH)
13.2.  Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Kits
13.2.2.Reagents
13.3.  Gastric Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Adenocarcinoma
13.3.2.Lymphoma
13.3.3.Gastrointestinal stromal tumor (GIST)
13.3.4.Carcinoid tumor
13.4.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospitals
13.4.2.Diagnostic centers
13.4.3.Others
13.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Gastric Cancer Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
14.1. Test Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Immunohistochemistry (IHC)
14.1.2.Fluorescent in situ hybridization (FISH)
14.2.  Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Kits
14.2.2.Reagents
14.3.  Gastric Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Adenocarcinoma
14.3.2.Lymphoma
14.3.3.Gastrointestinal stromal tumor (GIST)
14.3.4.Carcinoid tumor
14.4.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospitals
14.4.2.Diagnostic centers
14.4.3.Others
14.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Agilent Technologies Inc (U.S)
15.2.2.Thermo Fisher Scientific Inc (U.S)
15.2.3.Illumina Inc (Denmark)
15.2.4.Becton, Dickinson and Company (U.S)
15.2.5.GE Healthcare (U.K)
15.2.6.QIAGEN N.V (Netherlands)
15.2.7.Abbott Laboratories Inc (U.S)
15.2.8.Roche Diagnostics (Switzerland)
15.2.9.Siemens Healthcare (Germany)
15.2.10.Philips Healthcare (U.K)
15.2.11.R. Bard Inc (U.S)
16. Research Methodology 
17. Appendix and Abbreviations 
  • Agilent Technologies Inc (U.S)
  • Thermo Fisher Scientific Inc (U.S)
  • Illumina Inc (Denmark)
  • Becton, Dickinson and Company (U.S)
  • GE Healthcare (U.K)
  • QIAGEN N.V (Netherlands)
  • Abbott Laboratories Inc (U.S)
  • Roche Diagnostics (Switzerland)
  • Siemens Healthcare (Germany)
  • Philips Healthcare (U.K)
  • R. Bard Inc (U.S)

Adjacent Markets